MYOSTEATOSIS IN METASTATIC GYNECOLOGIC CANCER: CURRENT STATE OF THE PROBLEM
Keywords:
myosteatosis, gynecologic cancer, metastasis, chemotherapy toxicity, survival, computed tomographyAbstract
Myosteatosis, defined as fatty infiltration of skeletal muscle, is an important component of body composition disorders in oncology. In metastatic gynecologic cancers, this condition is frequently underestimated when relying on conventional anthropometric measures, despite its significant impact on treatment tolerance and prognosis. This review summarizes current evidence on the pathophysiological mechanisms of myosteatosis, its association with chemotherapy-related toxicity, and its influence on overall and progression-free survival. Computed tomography–derived muscle density is shown to be an independent prognostic factor of adverse oncologic outcomes, particularly in patients with preserved or increased body mass index. The integration of myosteatosis assessment into multifactorial risk stratification models may improve personalized management strategies for patients with metastatic gynecologic malignancies.
References
Amini, B., Boyle, S. P., Boutin, R. D., & Lenchik, L. (2019). Assessment of muscle density by computed tomography and magnetic resonance imaging in oncologic patients: Association with outcomes. Skeletal Radiology, 48(12), 1877–1885. https://doi.org/10.1007/s00256-019-03225-0
Baracos, V. E., Arribas, L., Sarlo, C., & Prado, C. M. (2018). Myosteatosis: A marker of muscle quality and predictor of survival in cancer patients. The Lancet Oncology, 19(9), e402–e412. https://doi.org/10.1016/S1470-2045(18)30340-3
Fearon, K., Strasser, F., Anker, S. D., Bosaeus, I., Bruera, E., Fainsinger, R. L., … Baracos, V. E. (2011). Definition and classification of cancer cachexia: An international consensus. The Lancet Oncology, 12(5), 489–495. https://doi.org/10.1016/S1470-2045(10)70218-7
Goodpaster, B. H., Theriault, R., Watkins, S. C., & Kelley, D. E. (2001). Intramuscular lipid content is increased in obesity and decreased by weight loss. Metabolism, 49(4), 467–472. https://doi.org/10.1016/S0026-0495(00)80010-4
Lokireddy, S., Wijesoma, I. W., Bonala, S., Wei, M., Sze, S. K., McFarlane, C., … Sharma, M. (2012). Myostatin induces degradation of sarcomeric proteins through an autophagy-dependent mechanism. American Journal of Physiology – Cell Physiology, 303(7), C650–C661. https://doi.org/10.1152/ajpcell.00114.2012
Martin, L., Birdsell, L., Macdonald, N., Reiman, T., Clandinin, M. T., McCargar, L. J., … Baracos, V. E. (2013). Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. Journal of Clinical Oncology, 31(12), 1539–1547. https://doi.org/10.1200/JCO.2012.45.2722
Mourtzakis, M., Prado, C. M., Lieffers, J. R., Reiman, T., McCargar, L. J., & Baracos, V. E. (2008). A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Applied Physiology, Nutrition, and Metabolism, 33(5), 997–1006. https://doi.org/10.1139/H08-075
Murphy, K. T., Lynch, G. S., & Ryall, J. G. (2010). Interleukin-6 signalling and skeletal muscle atrophy in cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 1(1), 47–54. https://doi.org/10.1007/s13539-010-0007-1
Prado, C. M., Baracos, V. E., McCargar, L. J., Reiman, T., Mourtzakis, M., Tonkin, K., … Sawyer, M. B. (2007). Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clinical Cancer Research, 13(11), 3264–3268. https://doi.org/10.1158/1078-0432.CCR-06-3067
Prado, C. M., Lieffers, J. R., McCargar, L. J., Reiman, T., Sawyer, M. B., Martin, L., & Baracos, V. E. (2008). Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts. The Lancet Oncology, 9(7), 629–635. https://doi.org/10.1016/S1470-2045(08)70153-0
Prado, C. M., Wells, J. C. K., Smith, S. R., Stephan, B. C. M., & Siervo, M. (2012). Sarcopenic obesity: A critical appraisal of the current evidence. Clinical Nutrition, 31(5), 583–601. https://doi.org/10.1016/j.clnu.2012.06.010
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1), 17–48. https://doi.org/10.3322/caac.21763
Shavkatovna S. S., Makhammatkulovich R. N. FEATURES OF SARCOPENIA IN CANCER PATIENTS //EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE. – 2024. – Т. 4. – №. 8. – С. 286-292.
Shavkatovna S. S., Makhammatkulovich R. N., Ugli M. S. T. ASPECTS OF SARCOPENIA SYNDROME IN ONCOLOGICAL PRACTICE: DIAGNOSIS AND TREATMENT //The American Journal of Medical Sciences and Pharmaceutical Research. – 2024. – Т. 6. – №. 02. – С. 16-25.
Makhammatkulovich, RAKHIMOV Nodir, et al. "ПАТОГЕНЕТИЧЕСКИЕ АСПЕКТЫ РАКОВОЙ АНОРЕКСИИ." JOURNAL OF BIOMEDICINE AND PRACTICE 8.4 (2023). Makhammatkulovich R. N. et al. PRACTICAL RECOMMENDATIONS FOR NUTRITIONAL SUPPORT FOR CERVICAL CANCER //JOURNAL OF BIOMEDICINE AND PRACTICE. – 2023. – Т. 8. – №. 2.
